Entera Bio
ENTX· Manufacturing· Fiscal year ends in December
CEO pay in FY2023Stock -17.8% in FY2023
Miranda Toledano is the CEO of Entera Bio and was paid $950 in FY2023 (Dec), up 40%.
Pay$100 in the stock at the end of FY21 → $21
Executives3
See all- 1Miranda ToledanoChief Executive Officer and directorFY2023
- 2Hillel GalitzerChief Operating OfficerFY2022
- 3Gregory BurshteinChief of Research and DevelopmentNot disclosed
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allEntera Bio paid its 2 named executives $1.3K in total in FY2023 (Dec). CEO Miranda Toledano was paid $950 of that.
| Name | ||
|---|---|---|
| Miranda ToledanoChief Executive Officer and director | ||
| Hillel GalitzerChief Operating Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Entera Bio. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board4
See all- Steven D. RubinDirector · 18 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive
- Yonatan MalcaDirector · 14 yr on the boardIndependentAudit, Compensation (Chair)—Paid as an executive
- Sean EllisDirector · 6 yr on the boardIndependentAudit, Nominating and Corporate Governance—Paid as an executive
- Haya TaitelDirector · 2 yr on the boardIndependentCompensation, Nominating and Corporate Governance (Chair)—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Jun 3, 2026 | FY2025 |
| Annual report | 10-K | Mar 27, 2026 | FY2025 |
| Proxy statement | DEF 14A | Jun 5, 2025 | FY2024 |
| Annual report | 10-K | Mar 28, 2025 | FY2024 |
| Proxy statement | DEF 14A | Jun 20, 2024 | FY2023 |
| Annual report | 10-K | Mar 8, 2024 | FY2023 |
